Summary of Grace Therapeutics FY Conference Call Company Overview - Company: Grace Therapeutics (NasdaqCM:GRCE) - Focus: Development of GTx-104 for the treatment of aneurysm subarachnoid hemorrhage (aSAH) - PDUFA Date: April 23, 2026, for GTx-104 approval Core Industry Insights - Disease Context: aSAH is a critical care condition with high mortality (one-third of patients do not survive) and morbidity (one-third suffer long-term effects) [3][4] - Current Treatment: The only FDA-approved drug for aSAH is nimodipine, which is administered orally and has significant limitations, including a dosing burden and poor pharmacokinetics [4][6] GTx-104 Innovation - Formulation: GTx-104 is the first aqueous formulation of nimodipine that can be administered via intravenous infusion, addressing the challenges of the oral formulation [5] - Clinical Advantages: - Over 90% of patients on oral nimodipine do not receive the full therapeutic dose due to hypotension and other complications [6][7] - IV administration shows better pharmacokinetics, with a 2-3x lower variability compared to oral [7][8] - Improved ICU workload management and reduced complications associated with oral administration [9] STRIVE-ON Study - Study Design: Phase 3 safety trial comparing IV GTx-104 to oral nimodipine, involving 100 patients across 30 high-volume academic centers [12][13] - Primary Endpoint: Clinically significant hypotension events; IV arm showed almost 20% fewer events compared to oral [15] - Relative Dose Intensity (RDI): 55% of IV patients achieved 95% or higher RDI, compared to only 8% in the oral group [16] - Efficacy Signals: Nearly 30% of IV patients showed good functional recovery, with zero bedridden patients at day 90 compared to 15-16% in the oral arm [17][18] Key Opinion Leader (KOL) Feedback - KOLs are enthusiastic about the potential for better hypotension control and higher dose compliance with GTx-104, which may lead to improved patient outcomes [19] Regulatory and Market Strategy - Regulatory Engagement: Positive interactions with the FDA leading up to the NDA submission, with no alarming issues raised [23] - Market Education: Ongoing efforts to educate healthcare professionals about the limitations of oral nimodipine and the benefits of GTx-104, including two major continuing medical education events attended by 10,000 healthcare professionals [25][26] Market Potential - Patient Population: Estimated 45,000 cases of aSAH annually in the U.S., with a focus on severe cases (Hunt and Hess grades 3-5) [32][41] - Value Proposition: Emphasis on hemodynamic stability, reliable drug exposure, and reduced ICU workload [33] Pricing Strategy - Ongoing work to determine pricing for GTx-104, considering the current market for oral nimodipine and the need to maximize patient access [34][36] Intellectual Property - Protection: Orphan drug designation expected to convert to exclusivity upon approval, with patents extending to 2043 for method of use and 2037 for formulations [43][44] Conclusion - Grace Therapeutics is positioned to potentially transform the treatment landscape for aSAH with GTx-104, addressing significant limitations of current therapies and aiming for a strong market entry following FDA approval.
Grace Therapeutics (NasdaqCM:GRCE) FY Conference Transcript